Hélène Haguet

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

Jonathan Douxfils, Hélène Haguet, François Mullier et al. · JAMA Oncology · 2016 · 188 citations · Full text

Medicine, Hematology, Pharmacology +11

Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need

Jonathan Douxfils, Laure Morimont, Anne‐Sophie Delvigne et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2019 · 46 citations

Medicine, Gynecology, Clinical Biochemistry +13

NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study

Laure Morimont, Mélanie Dechamps, Clara David et al. · Biomolecules · 2022 · 44 citations · Full text

Veterinary Medicine, Immunology, Pathology +16

Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia

Damien Gheldof, Hélène Haguet, Jean‐Michel Dogné et al. · Journal of Thrombosis and Thrombolysis · 2017 · 33 citations

Medicine, Cell Biology, Hematology +16

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

Hélène Haguet, Céline Bouvy, Anne-Sophie Delvigne et al. · Frontiers in Pharmacology · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16